Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in Egypt / NCT07418606
Active, not recruiting Observational

Corneal Endothelial Cell Changes In Silicon Filled Eye

NCT07418606 · tracked via the Priya Life Science Egypt tracker
Sponsor
Minia University
Phase
Observational
Started
2025-06-15
Last updated
2026-06-30

Condition(s) studied

Rhegmatogenous Macula-off Retinal Detachment

Study summary

The aim of this study is to evaluate corneal endothelial cell changes after pars plana vitrectomy in Rhegmatogenous Retinal detachment , compare the results using different silicon oil viscositites , and assess whether these changes are reversible after silicone removal or not .

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: \- All patients with Rhegmatodenous retinal detachment which need PPV will be included in this study. Exclusion Criteria: * Patients with corneal dystrophies or degeneration. * Patients with a history of refractive surgery, either corneal or phakic lOL implantation. * Patients with a history of keratoplasty. * Patients with history of retinal detachment surgery in the same eye. * Recurrent cases during the follow-up period will be removed from the study. 6. patients with gas tamponade 7. patients with silicon oil 1000 cs 8. patients with Retinal pathologies such as macular hole , diabetic changes 9. patients undergo phacovitrectomy

Primary outcome measure(s)

  • Corneal Endothelial Cell Changes In Silicon Filled Eye . — 4 months
    Corneal Endothelial Cell Changes cell density ( cells/ mm) , coeffient variation(%) In Silicon Filled Eye at 1 and 3 months postoperative

Trial sites (1)

FacilityCityRegionStatus
Minia University Minya Egypt

More Minia University trials in Egypt

Comparative Study Between the Effect of Dexmedetomidine ,Midazolam or Bupivacaine Packing During FESS on Surgical Field Visualization Enrolling by invitation
CGF Partial Pulpotomy Versus Endodontic Treatment Starting soon
Mesopancreatic Excision for Pancreatic Duct Adenocarcinoma. Recruiting
Comparison Between Socket Shield and Conventional Techniques in Immediate Implant Placement. Recruiting
Temporary Uterine Tourniquet Application Versus Local Myometrial Epinephrine Injection During Laparoscopic Myomectomy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07418606 on ClinicalTrials.gov ↗ ← All trials in Egypt